IL-36 signalling as a therapeutic target in pustular psoriasis

IL-36 信号传导作为脓疱型银屑病的治疗靶点

• 批准号: 2072060
• 金额: --
• 依托单位: King's College London
• 依托单位国家: 英国
• 项目类别: Studentship
• 财政年份: 2018
• 资助国家: 英国
• 起止时间: 2018 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=studentship-2072060
• 关键词: IL; 36; signalling; therapeutic; target

The aim of this study is to characterise the immune responses driven by interleukin-(IL) 36, an inflammatory molecule that is currently being targeted for the treatment of pustular psoriasis. We specifically propose to combine our expertise in basic science (Capon), clinical dermatology (Smith) and drug development (Boehringer-Ingelheim), to achieve the following objectives:I: Identifying the immune cell types that are sensitive to IL-36. II: Dissecting the effects of abnormal IL-36 activity.III: Determining whether the effects of pustular psoriasis mutations can be reversed by IL-36 blockade.

本研究的目的是观察白细胞介素（IL）36驱动的免疫反应，IL 36是一种炎症分子，目前被靶向用于治疗脓疱性银屑病。我们特别建议将我们在基础科学（Capon）、临床皮肤病学（Smith）和药物开发（Boehringer-Ingelheim）方面的专业知识联合收割机，以实现以下目标：I：鉴定对IL-36敏感的免疫细胞类型。第二章：解剖异常IL-36活性的影响。III：确定脓疱性银屑病突变的影响是否可以通过IL-36阻断逆转。